Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $108.18M by Medicaid between Jan 2018 and Dec 2024, across 574 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
NEW YORK, NY 10037
NEW YORK, NY 10037
33aNPI1033124961assigned 07/29/2006
33bProvider typeInternal Medicine Physician
28Total paid$108.18M
24GClaims2,390,009
24DCodes billed574
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#8 of 6,049
Median peer was paid$11K
This provider vs. median9,563×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,188 | $215K | |
| 2019 | 146,733 | $6.09M | |
| 2020 | 366,036 | $17.37M | |
| 2021 | 563,610 | $23.83M | |
| 2022 | 540,536 | $25.12M | |
| 2023 | 392,179 | $18.76M | |
| 2024incomplete | 346,727 | $16.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 79,676 | 72,784 | $14.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 62,750 | 56,846 | $11.32M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.5% | 87,720 | 76,633 | $8.11M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.4% | 59,682 | 53,341 | $6.88M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 4.9% | 5,867 | 5,195 | $5.33M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 16,953 | 15,597 | $3.45M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 40,715 | 35,876 | $2.23M |
| H2012 | Behavioral health day treatment, per hour | 2.0% | 19,483 | 2,298 | $2.17M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 11,465 | 10,870 | $1.93M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 28,528 | 25,705 | $1.78M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.6% | 10,990 | 10,107 | $1.74M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.6% | 10,348 | 10,031 | $1.68M |
562 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 7,376 | $1.52M |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 157,623 | $1.49M |
| 90832 | Psychotherapy session, about 30 minutes | 1.3% | 7,745 | $1.43M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 14,380 | $1.33M |
| 90834 | Psychotherapy session, about 45 minutes | 1.2% | 5,714 | $1.30M |
| 99203 | Doctor's office visit, new patient (routine) | 1.1% | 10,372 | $1.23M |
| 99205 | Prolong outpt/office vis | <1% | 4,561 | $894K |
| 81408 | <1% | 613 | $836K | |
| 99443 | <1% | 6,096 | $827K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 13,375 | $761K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 4,162 | $754K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 26,005 | $749K |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 5,340 | $731K |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 4,488 | $717K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,149 | $700K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 10,243 | $663K |
| 99442 | <1% | 8,221 | $656K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 64,046 | $583K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 22,681 | $557K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 25,494 | $533K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 30,476 | $531K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,156 | $515K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,504 | $511K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 26,621 | $451K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 10,908 | $412K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,042 | $411K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 616 | $409K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 545 | $406K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,015 | $405K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 11,525 | $399K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,350 | $386K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 605 | $383K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,757 | $375K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,864 | $366K |
| 86480 | <1% | 5,976 | $361K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,417 | $352K |
| 90461 | <1% | 11,982 | $351K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18,302 | $340K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,232 | $336K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 2,171 | $334K |
| 76641 | <1% | 2,681 | $333K | |
| 93970 | <1% | 1,318 | $310K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,682 | $305K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,803 | $303K |
| 80061 | Lipid panel | <1% | 26,984 | $301K |
| 70486 | <1% | 2,335 | $299K | |
| S9485 | Crisis intervention mental health services, per diem | <1% | 268 | $285K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 3,154 | $281K |
| 85027 | <1% | 88,287 | $280K | |
| 86703 | <1% | 21,081 | $277K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 3,062 | $276K |
| 80076 | <1% | 44,437 | $275K | |
| 87536 | <1% | 2,951 | $272K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,854 | $272K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,986 | $265K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,408 | $252K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,702 | $250K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 7,090 | $247K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,533 | $242K |
| 12001 | <1% | 989 | $237K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,722 | $236K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,838 | $232K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 32,005 | $232K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 25,864 | $227K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,480 | $208K |
| 99441 | <1% | 4,676 | $206K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,365 | $203K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,770 | $194K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,232 | $192K |
| 86850 | <1% | 10,675 | $184K | |
| 12011 | <1% | 865 | $178K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,549 | $177K |
| 0002A | <1% | 6,057 | $175K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,100 | $175K |
| 86360 | <1% | 3,567 | $168K | |
| 0001A | <1% | 6,243 | $162K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,866 | $153K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,457 | $152K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,234 | $148K |
| 90837 | Psychotherapy session, about an hour | <1% | 802 | $146K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,140 | $143K |
| 90677 | <1% | 1,133 | $143K | |
| 86780 | <1% | 14,155 | $141K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 602 | $138K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,246 | $137K |
| 86359 | <1% | 3,561 | $134K | |
| 83655 | <1% | 11,183 | $133K | |
| 83970 | <1% | 3,703 | $133K | |
| 80053 | Comprehensive metabolic panel | <1% | 10,631 | $132K |
| 90750 | <1% | 1,581 | $131K | |
| 81161 | <1% | 616 | $125K | |
| 99381 | <1% | 2,138 | $123K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 9,005 | $122K |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 2,144 | $120K |
| 90651 | <1% | 1,927 | $118K | |
| 86901 | <1% | 10,717 | $116K | |
| 59025 | Fetal non-stress test | <1% | 1,110 | $115K |
| 76830 | Ultrasound, transvaginal | <1% | 2,455 | $114K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 845 | $112K |
| 76801 | <1% | 1,166 | $109K | |
| 86803 | <1% | 9,639 | $108K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,078 | $108K |
| 77065 | Tomosynthesis, mammo | <1% | 877 | $107K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,060 | $104K |
| 90686 | <1% | 11,256 | $103K | |
| 82948 | <1% | 37,117 | $103K | |
| 10060 | <1% | 633 | $102K | |
| 71271 | <1% | 413 | $100K | |
| 81405 | <1% | 502 | $100K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 8,278 | $100K |
| 72197 | <1% | 221 | $97K | |
| 81329 | <1% | 790 | $95K | |
| 76770 | <1% | 617 | $94K | |
| 82805 | <1% | 10,460 | $91K | |
| 90715 | <1% | 3,333 | $91K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 593 | $91K |
| 81025 | <1% | 22,705 | $91K | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 960 | $90K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,740 | $86K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 2,455 | $86K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,538 | $85K |
| 86900 | <1% | 10,722 | $84K | |
| D0330 | Panoramic radiographic image | <1% | 5,596 | $82K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,507 | $81K |
| 12002 | <1% | 336 | $80K | |
| 0004A | <1% | 2,216 | $80K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 503 | $80K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 1,127 | $77K |
| 87340 | <1% | 9,974 | $76K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,390 | $75K |
| 99243 | <1% | 536 | $73K | |
| 82728 | <1% | 7,248 | $71K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 481 | $69K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 794 | $68K |
| 71250 | <1% | 292 | $68K | |
| 20610 | <1% | 511 | $68K | |
| 81361 | <1% | 549 | $66K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,642 | $65K |
| 73630 | <1% | 3,127 | $65K | |
| 82607 | <1% | 4,973 | $63K | |
| 97802 | <1% | 1,866 | $63K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,101 | $62K |
| 92015 | Determination of refractive state | <1% | 2,592 | $61K |
| 97803 | <1% | 1,958 | $61K | |
| 90734 | <1% | 1,611 | $60K | |
| 97162 | <1% | 475 | $60K | |
| 86706 | <1% | 6,592 | $58K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 6,784 | $58K |
| 86769 | <1% | 1,775 | $57K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 2,856 | $56K |
| 88312 | <1% | 990 | $56K | |
| 20552 | <1% | 695 | $56K | |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 306 | $55K |
| 92250 | <1% | 1,173 | $53K | |
| 96127 | <1% | 15,893 | $52K | |
| 73610 | <1% | 2,724 | $51K | |
| 87535 | <1% | 1,487 | $51K | |
| 87800 | <1% | 1,532 | $49K | |
| 73564 | <1% | 2,206 | $48K | |
| 90714 | <1% | 3,396 | $48K | |
| 92002 | <1% | 534 | $48K | |
| 81401 | <1% | 518 | $48K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 98 | $46K |
| 99383 | <1% | 1,367 | $46K | |
| 99384 | <1% | 739 | $46K | |
| 77062 | <1% | 298 | $46K | |
| 83880 | <1% | 2,814 | $45K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,314 | $44K |
| 90746 | <1% | 750 | $43K | |
| 90732 | <1% | 443 | $43K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,222 | $42K |
| 81257 | <1% | 606 | $42K | |
| 99201 | <1% | 535 | $41K | |
| 76536 | <1% | 355 | $41K | |
| 0072A | <1% | 1,035 | $40K | |
| 81243 | <1% | 887 | $40K | |
| 83020 | <1% | 3,135 | $40K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 542 | $40K |
| 0124A | <1% | 890 | $40K | |
| 73130 | <1% | 2,451 | $39K | |
| 90670 | <1% | 3,049 | $39K | |
| 80320 | <1% | 9,657 | $39K | |
| 81001 | <1% | 26,183 | $39K | |
| 82746 | <1% | 3,423 | $39K | |
| 0071A | <1% | 1,069 | $37K | |
| 86762 | <1% | 2,944 | $37K | |
| 84702 | <1% | 6,344 | $37K | |
| 84439 | <1% | 4,739 | $36K | |
| 73560 | <1% | 1,112 | $36K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,295 | $35K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 177 | $35K |
| 73030 | <1% | 2,094 | $34K | |
| 88142 | <1% | 1,549 | $34K | |
| 72100 | <1% | 1,306 | $34K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 971 | $34K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 753 | $32K |
| 86765 | <1% | 2,884 | $32K | |
| 82043 | <1% | 6,385 | $31K | |
| 76818 | <1% | 276 | $31K | |
| 86704 | <1% | 3,175 | $31K | |
| 54150 | <1% | 42 | $30K | |
| 73110 | <1% | 1,625 | $30K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 1,380 | $30K |
| 83540 | <1% | 6,666 | $30K | |
| 29125 | <1% | 246 | $29K | |
| D1120 | Dental cleaning, child | <1% | 2,968 | $29K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,174 | $28K |
| 87486 | <1% | 1,394 | $28K | |
| 84425 | <1% | 1,667 | $28K | |
| 91320 | <1% | 508 | $28K | |
| 97014 | <1% | 1,935 | $28K | |
| 99382 | <1% | 348 | $27K | |
| 94729 | <1% | 541 | $27K | |
| 83001 | <1% | 1,553 | $27K | |
| 83550 | <1% | 4,613 | $27K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 484 | $27K |
| 92550 | <1% | 777 | $26K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,086 | $26K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,520 | $25K |
| 94010 | <1% | 396 | $25K | |
| 83735 | <1% | 18,437 | $25K | |
| 93971 | <1% | 607 | $25K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,063 | $24K |
| 84146 | <1% | 1,355 | $24K | |
| 73502 | <1% | 918 | $24K | |
| 85610 | <1% | 9,762 | $23K | |
| 84703 | <1% | 11,817 | $23K | |
| 97032 | <1% | 1,359 | $23K | |
| 84153 | <1% | 1,595 | $23K | |
| 90480 | <1% | 591 | $22K | |
| 87581 | <1% | 1,394 | $22K | |
| 81400 | <1% | 511 | $22K | |
| 86787 | <1% | 2,151 | $22K | |
| 81255 | <1% | 516 | $22K | |
| 92133 | <1% | 499 | $21K | |
| 90999 | Dialysis (unlisted procedure) | <1% | 101 | $21K |
| 90620 | <1% | 916 | $21K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,107 | $21K |
| 97010 | <1% | 2,903 | $21K | |
| 99385 | <1% | 262 | $21K | |
| 81251 | <1% | 519 | $20K | |
| D0120 | Dental checkup, returning patient | <1% | 2,232 | $20K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 1,901 | $20K |
| 81200 | <1% | 518 | $20K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 353 | $19K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 42 | $19K |
| 84481 | <1% | 1,414 | $19K | |
| 82951 | <1% | 1,739 | $18K | |
| 90698 | <1% | 3,358 | $18K | |
| 97116 | <1% | 603 | $18K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,666 | $17K |
| 94727 | <1% | 458 | $17K | |
| 85730 | <1% | 7,675 | $17K | |
| 81260 | <1% | 517 | $17K | |
| 86735 | <1% | 1,588 | $16K | |
| 97166 | <1% | 116 | $16K | |
| 84255 | <1% | 698 | $16K | |
| 77061 | <1% | 120 | $16K | |
| 83002 | <1% | 953 | $16K | |
| 82105 | <1% | 1,244 | $16K | |
| 86003 | <1% | 651 | $16K | |
| H0001 | Alcohol and/or drug assessment | <1% | 87 | $16K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 50 | $15K |
| 73590 | <1% | 1,353 | $15K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 238 | $15K |
| 87521 | Neg quan hep c or qual rna | <1% | 476 | $15K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 69 | $15K |
| 90707 | <1% | 986 | $14K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 3,516 | $14K |
| 84402 | <1% | 587 | $14K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 424 | $14K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 17,310 | $13K |
| 87517 | <1% | 315 | $13K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 342 | $13K |
| D0274 | Bitewings - four radiographic images | <1% | 2,188 | $13K |
| 84484 | <1% | 12,216 | $13K | |
| 72131 | <1% | 100 | $13K | |
| 99401 | <1% | 243 | $12K | |
| 73090 | <1% | 995 | $12K | |
| 90633 | <1% | 1,941 | $12K | |
| 86708 | <1% | 1,092 | $12K | |
| 90744 | <1% | 1,880 | $12K | |
| 87081 | <1% | 2,920 | $11K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 25 | $11K |
| 76870 | <1% | 186 | $11K | |
| D1206 | Topical application of fluoride varnish | <1% | 1,739 | $11K |
| 84403 | <1% | 463 | $11K | |
| 92557 | <1% | 329 | $11K | |
| 90656 | <1% | 903 | $11K | |
| 74178 | <1% | 31 | $11K | |
| 99051 | <1% | 1,263 | $11K | |
| 82570 | <1% | 2,618 | $10K | |
| 99242 | <1% | 98 | $10K | |
| 74018 | <1% | 498 | $10K | |
| 90716 | <1% | 912 | $9K | |
| 73140 | <1% | 618 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,751 | $9K |
| 84590 | <1% | 839 | $9K | |
| 87186 | <1% | 2,045 | $9K | |
| 99402 | <1% | 118 | $9K | |
| 83690 | <1% | 12,064 | $9K | |
| 82525 | <1% | 762 | $9K | |
| 96161 | <1% | 1,900 | $9K | |
| 80323 | <1% | 952 | $9K | |
| 82677 | <1% | 420 | $9K | |
| 69210 | <1% | 115 | $9K | |
| 90681 | <1% | 1,493 | $9K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 114 | $9K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 333 | $9K |
| D1110 | Prophylaxis - adult | <1% | 684 | $8K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 403 | $8K |
| 84630 | <1% | 883 | $8K | |
| 84100 | <1% | 4,596 | $8K | |
| 82803 | <1% | 3,528 | $8K | |
| 12013 | <1% | 32 | $8K | |
| 73120 | <1% | 331 | $7K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 1,941 | $7K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 1,199 | $7K |
| 86696 | <1% | 512 | $7K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 70 | $7K |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,144 | $7K |
| 84156 | <1% | 2,328 | $7K | |
| 72141 | <1% | 14 | $6K | |
| 97161 | <1% | 60 | $6K | |
| 86140 | <1% | 1,997 | $6K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 133 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 523 | $6K |
| 72170 | <1% | 915 | $6K | |
| 86592 | <1% | 1,671 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,711 | $6K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,877 | $6K |
| 81003 | <1% | 4,072 | $6K | |
| 85651 | <1% | 1,940 | $6K | |
| 82955 | <1% | 628 | $6K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 34 | $6K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,163 | $5K |
| 76820 | <1% | 115 | $5K | |
| 84704 | <1% | 420 | $5K | |
| 82670 | <1% | 206 | $5K | |
| 76000 | <1% | 52 | $5K | |
| 0031A | <1% | 141 | $5K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 903 | $5K |
| D1351 | Sealant - per tooth | <1% | 594 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,131 | $5K |
| 86336 | <1% | 420 | $5K | |
| 86695 | <1% | 458 | $5K | |
| 84550 | <1% | 1,676 | $5K | |
| 87338 | <1% | 415 | $5K | |
| 90710 | <1% | 791 | $5K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 42 | $5K |
| 93325 | <1% | 181 | $5K | |
| 82610 | <1% | 342 | $5K | |
| 86038 | <1% | 508 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,873 | $4K |
| 84134 | <1% | 813 | $4K | |
| 97804 | <1% | 148 | $4K | |
| 85045 | <1% | 2,160 | $4K | |
| 73080 | <1% | 373 | $4K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 287 | $4K |
| 86141 | <1% | 527 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,245 | $4K |
| 90674 | <1% | 217 | $4K | |
| 82785 | <1% | 290 | $4K | |
| 92134 | <1% | 90 | $4K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 1,172 | $4K |
| 88304 | <1% | 148 | $3K | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 454 | $3K |
| 86593 | <1% | 1,218 | $3K | |
| 72070 | <1% | 124 | $3K | |
| 31575 | <1% | 27 | $3K | |
| 82550 | <1% | 2,735 | $3K | |
| 90696 | <1% | 689 | $3K | |
| 0081A | <1% | 83 | $3K | |
| 83615 | <1% | 824 | $3K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,024 | $3K |
| 73070 | <1% | 244 | $3K | |
| H0049 | Alcohol and/or drug screening | <1% | 50 | $3K |
| 90694 | <1% | 157 | $3K | |
| 77080 | <1% | 87 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,849 | $3K |
| 82248 | <1% | 608 | $3K | |
| 84207 | <1% | 102 | $3K | |
| 85379 | <1% | 1,762 | $3K | |
| 73552 | <1% | 232 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,305 | $2K |
| 92227 | <1% | 158 | $2K | |
| 80165 | <1% | 371 | $2K | |
| D0270 | <1% | 431 | $2K | |
| 96376 | <1% | 2,072 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 525 | $2K |
| 73060 | <1% | 206 | $2K | |
| 92083 | <1% | 37 | $2K | |
| 73562 | <1% | 297 | $2K | |
| 80321 | <1% | 137 | $2K | |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 36 | $2K |
| 96367 | <1% | 87 | $2K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 12 | $2K |
| 99386 | <1% | 13 | $2K | |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 25 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,954 | $2K |
| 29130 | <1% | 13 | $2K | |
| 93308 | <1% | 12 | $2K | |
| 83516 | <1% | 182 | $2K | |
| 74240 | <1% | 12 | $2K | |
| 88141 | <1% | 146 | $2K | |
| 99408 | <1% | 306 | $2K | |
| 85007 | <1% | 2,531 | $2K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 48 | $2K |
| 82652 | <1% | 43 | $1K | |
| 31231 | <1% | 12 | $1K | |
| 73620 | <1% | 121 | $1K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 3,150 | $1K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 16 | $1K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 5,329 | $1K |
| 73600 | <1% | 127 | $1K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 132 | $1K |
| 90662 | <1% | 49 | $1K | |
| 88104 | <1% | 37 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,161 | $1K |
| 95930 | <1% | 715 | $1K | |
| 99403 | <1% | 14 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 883 | $1K |
| 85220 | <1% | 77 | $1K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 962 | $1K |
| 76775 | <1% | 34 | $1K | |
| 85240 | <1% | 84 | $1K | |
| 29515 | <1% | 15 | $1K | |
| 86580 | <1% | 132 | $1K | |
| 85306 | <1% | 78 | $1K | |
| 82330 | <1% | 235 | $1K | |
| 0003A | <1% | 26 | $1K | |
| 85303 | <1% | 78 | $988.23 | |
| J2501 | Injection, paricalcitol, 1 mcg | <1% | 108 | $982.31 |
| Q3014 | Telehealth originating site facility fee | <1% | 401 | $964.52 |
| 82310 | <1% | 453 | $865.78 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,162 | $851.45 |
| 71101 | <1% | 67 | $813.39 | |
| 85305 | <1% | 75 | $793.10 | |
| D4341 | <1% | 56 | $779.58 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 164 | $776.08 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 173 | $774.48 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 988 | $746.97 |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 17 | $743.29 |
| 87420 | <1% | 272 | $729.19 | |
| 83090 | <1% | 46 | $726.31 | |
| 92579 | <1% | 14 | $710.07 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,685 | $672.63 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 169 | $660.77 |
| 0012A | <1% | 33 | $658.83 | |
| 82962 | <1% | 889 | $655.89 | |
| 82627 | <1% | 28 | $650.97 | |
| 82274 | <1% | 57 | $638.24 | |
| 90653 | <1% | 21 | $637.15 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,393 | $628.29 |
| 82010 | <1% | 716 | $612.31 | |
| 87522 | Neg quan hep c or qual rna | <1% | 14 | $610.50 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 4,493 | $609.78 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 251 | $598.58 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,351 | $582.25 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 670 | $577.65 |
| 82247 | <1% | 123 | $577.41 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $576.41 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,135 | $576.34 |
| 96380 | <1% | 62 | $558.72 | |
| 99499 | <1% | 4,078 | $553.42 | |
| D0603 | <1% | 229 | $509.55 | |
| 92551 | <1% | 1,583 | $500.09 | |
| 86430 | <1% | 102 | $484.70 | |
| 0082A | <1% | 12 | $477.35 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 4,299 | $463.84 |
| 0011A | <1% | 34 | $456.10 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 61 | $447.24 |
| 80069 | <1% | 57 | $438.01 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 125 | $414.03 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,836 | $406.91 |
| 92504 | <1% | 12 | $400.29 | |
| D9990 | <1% | 64 | $385.00 | |
| 86225 | <1% | 39 | $356.75 | |
| 90678 | <1% | 15 | $353.71 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,346 | $337.46 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 112 | $336.81 |
| 83992 | <1% | 57 | $334.15 | |
| 73660 | <1% | 12 | $307.49 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 3,346 | $303.48 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 28 | $300.78 |
| 74019 | <1% | 15 | $286.26 | |
| T2022 | Case management, per month | <1% | 12 | $273.29 |
| D0191 | <1% | 474 | $267.60 | |
| 92558 | <1% | 17 | $259.20 | |
| 88302 | <1% | 25 | $259.13 | |
| B4087 | Gastrostomy/jejunostomy tube, standard, any material, any type, each | <1% | 14 | $256.51 |
| 83525 | <1% | 26 | $238.34 | |
| 94761 | <1% | 31 | $215.13 | |
| 99000 | <1% | 12 | $212.81 | |
| 94799 | <1% | 13 | $206.13 | |
| 88300 | <1% | 13 | $199.27 | |
| J1815 | Injection, insulin, per 5 units | <1% | 581 | $192.03 |
| 87070 | <1% | 54 | $180.10 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 122 | $174.40 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 80 | $173.26 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 189 | $157.03 |
| 83718 | <1% | 28 | $131.03 | |
| 99173 | <1% | 1,728 | $126.46 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 26 | $126.20 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 100 | $126.08 |
| D0272 | Bitewings - two radiographic images | <1% | 37 | $116.80 |
| 96160 | <1% | 32 | $113.83 | |
| 84478 | <1% | 28 | $110.66 | |
| 99152 | <1% | 24 | $106.64 | |
| 82465 | <1% | 31 | $99.02 | |
| 73100 | <1% | 12 | $81.28 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 192 | $81.10 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 171 | $78.66 |
| D1354 | <1% | 15 | $75.00 | |
| 83605 | <1% | 58 | $74.80 | |
| 83021 | <1% | 82 | $73.11 | |
| 81015 | <1% | 30 | $72.89 | |
| 82565 | <1% | 13 | $62.30 | |
| 90685 | <1% | 160 | $57.53 | |
| 90723 | <1% | 13 | $53.55 | |
| 82150 | <1% | 30 | $46.13 | |
| 87110 | <1% | 15 | $34.67 | |
| 94760 | <1% | 330 | $33.29 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 633 | $32.35 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 39 | $30.49 |
| 87040 | <1% | 30 | $26.62 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 16 | $24.06 |
| 87071 | <1% | 28 | $19.53 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 22 | $19.46 |
| G0008 | Administration of influenza virus vaccine | <1% | 45 | $18.70 |
| 84512 | <1% | 30 | $17.99 | |
| 90648 | <1% | 12 | $17.85 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 15 | $12.73 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 26 | $3.52 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 27 | $0.49 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 14 | $0.17 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 12 | $0.16 |
| 1160F | <1% | 2,830 | $0.15 | |
| 1159F | <1% | 3,729 | $0.15 | |
| 3078F | <1% | 46,262 | $0.08 | |
| 3074F | <1% | 41,686 | $0.08 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 94 | $0.00 |
| 3077F | 0% | 11,055 | $0.00 | |
| 99080 | 0% | 1,623 | $0.00 | |
| 3051F | 0% | 17 | $0.00 | |
| 48510 | 0% | 382 | $0.00 | |
| 98960 | 0% | 13 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 19 | $0.00 |
| 2022F | 0% | 13 | $0.00 | |
| 99429 | 0% | 225 | $0.00 | |
| 3079F | 0% | 15,591 | $0.00 | |
| 3075F | 0% | 14,565 | $0.00 | |
| D1330 | 0% | 347 | $0.00 | |
| 3080F | 0% | 5,105 | $0.00 | |
| 1220F | 0% | 800 | $0.00 | |
| D1310 | 0% | 91 | $0.00 | |
| 99406 | 0% | 373 | $0.00 | |
| 3044F | 0% | 69 | $0.00 | |
| 4293F | 0% | 149 | $0.00 | |
| 87620 | 0% | 46 | $0.00 | |
| 3008F | 0% | 15 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.